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Abstract
BACKGROUND—The immunopathogenesis of type 1 diabetes mellitus is associated with T-
lymphocyte autoimmunity. However, there is growing evidence that B lymphocytes play a role in 
many T-lymphocyte–mediated diseases. It is possible to achieve selective depletion of B 
lymphocytes with rituximab, an anti-CD20 monoclonal antibody. This phase 2 study evaluated the 
role of B-lymphocyte depletion in patients with type 1 diabetes.
METHODS—We conducted a randomized, double-blind study in which 87 patients between 8 
and 40 years of age who had newly diagnosed type 1 diabetes were assigned to receive infusions 
of rituximab or placebo on days 1, 8, 15, and 22 of the study. The primary outcome, assessed 1 
year after the first infusion, was the geometric mean area under the curve (AUC) for the serum C-
peptide level during the first 2 hours of a mixed-meal tolerance test. Secondary outcomes included 
safety and changes in the glycated hemoglobin level and insulin dose.
RESULTS—At 1 year, the mean AUC for the level of C peptide was significantly higher in the 
rituximab group than in the placebo group. The rituximab group also had significantly lower levels 
of glycated hemoglobin and required less insulin. Between 3 months and 12 months, the rate of 
decline in C-peptide levels in the rituximab group was significantly less than that in the placebo 
group. CD19+ B lymphocytes were depleted in patients in the rituximab group, but levels 
increased to 69% of baseline values at 12 months. More patients in the rituximab group than in the 
placebo group had adverse events, mostly grade 1 or grade 2, after the first infusion. The reactions 
appeared to be minimal with subsequent infusions. There was no increase in infections or 
neutropenia with rituximab.
CONCLUSIONS—A four-dose course of rituximab partially preserved beta-cell function over a 
period of 1 year in patients with type 1 diabetes. The finding that B lymphocytes contribute to the 
pathogenesis of type 1 diabetes may open a new pathway for exploration in the treatment of 
patients with this condition. (ClinicalTrials.gov number, NCT00279305.)
THE AUTOIMMUNE DESTRUCTION OF BETA cells in patients with type 1 diabetes 
mellitus begins before the onset of hyperglycemia, but measurement of C-peptide responses 
at the time of diagnosis indicates that patients retain some beta-cell function at this stage. 
Furthermore, the persistence of residual beta-cell function is associated with reductions of 
severe hypoglycemic episodes and complications.1 Thus, an intervention that maintains 
endogenous insulin production might improve the management of type 1 diabetes and 
reduce long-term complications.
Although the presence of autoantibodies is a diagnostic criterion, the immunopathogenesis 
of beta-cell destruction in type 1 diabetes is typically associated with T-lymphocyte 
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autoimmunity. Immunosuppressive or immunomodulatory drugs have been administered 
early in the course of type 1 diabetes in some clinical trials,2–7 including trials testing the 
effectiveness of humanized anti-CD3 antibody and glutamic acid decarboxylase.5–7
Many T-lymphocyte–mediated diseases include a B-lymphocyte component. B lymphocytes 
can play a crucial role as antigen-presenting cells,8,9 expressing high levels of class II major-
histocompatibility-complex antigens10–13 and generating cryptic peptides to which T 
lymphocytes are not tolerant.14 For example, in nonobese mice with diabetes, the disease 
can be inhibited by depletion of B lymphocytes.8,15,16 In contrast to these findings in animal 
models, a report of type 1 diabetes in a child with X-linked agammaglobulinemia suggests 
that the presence of B lymphocytes is not essential to the development of type 1 diabetes.17
B lymphocytes can be selectively depleted with the anti-CD20 monoclonal antibody 
rituximab (Rituxan, Genentech and Biogen Idec).18–20 We tested the hypothesis that 
transient elimination of B lymphocytes with rituximab would decrease immune-mediated 
destruction of beta cells and result in preserved beta-cell function in patients with type 1 
diabetes of recent onset.
METHODS
PATIENTS AND STUDY DESIGN
A total of 126 patients between the ages of 8 and 45 years who had type 1 diabetes 
underwent screening at 12 sites in the United States and Canada for the presence of at least 
one type of detectable diabetes autoantibody: microinsulin autoantibody (in patients who 
had started taking insulin in the preceding 7 days), glutamic acid decarboxylase 65, islet-cell 
antigen 512, or islet-cell autoantibody. Enrollment occurred between May 2006 and August 
2007; all patients had completed 1 year of follow-up by August 2008. Patients underwent 
mixed-meal tolerance testing within 3 weeks to 3 months after the diagnosis had been 
established and were required to have stimulated peak C-peptide levels of at least 0.2 pmol 
per milliliter to be eligible for enrollment. The initial patients enrolled were 12 years of age 
or older. After a safety assessment by the data and safety monitoring board, children as 
young as 8 years of age were included. Eligible patients underwent randomization in a 2:1 
ratio of active treatment to placebo, stratified according to clinical center. Both participants 
and research staff were unaware of the treatment assignments. However, clinical blinding 
was difficult because of the infusion reactions that predominated in the rituximab group.
The protocol and consent documents were approved by an independent ethics committee or 
institutional review board at each participating center. All patients (or their parents) provided 
written informed consent; patients under 18 years of age provided written assent. An 
independent data and safety monitoring board met every 6 months and conducted quarterly 
summary safety reviews. A TrialNet medical monitor (who was unaware of the treatment 
assignments) reviewed all adverse events.
Genentech and Biogen Idec provided the rituximab and the matching placebo but had no 
involvement with the design, conduct, or management of the study; the collection, analysis, 
or interpretation of the data; or the preparation of the manuscript. All the authors were 
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involved in the conduct of the study and the collection and review of study data. The 
principal investigator wrote the first draft of the manuscript. The writing group, which 
consisted of five of the authors, made the decision to submit the manuscript for publication. 
The other authors reviewed and commented on various versions of the manuscript and 
suggested revisions. The members of the writing group assume responsibility for the overall 
content and integrity of the article. There are no agreements concerning confidentiality of 
the data between the sponsor and the authors or their institutions. The authors did provide 
Genentech a copy of the original manuscript before submission.
One intravenous infusion of rituximab (375 mg per square meter of body-surface area) in a 
solution (pH 6.5) with 9 mg of sodium chloride per milliliter, 7.35 mg of sodium citrate 
dihydrate per milliliter, 0.7 mg of polysorbate 80 per milliliter, and water for injection or of 
an identical placebo solution without the rituximab was given on study days 1, 8, 15, and 22. 
The four doses constituted one course of treatment. The patients received acetaminophen 
and diphenhydramine before each infusion to attenuate infusion-related events. 
Corticosteroids were not administered, in order to avoid any potential effect on plasma 
glucose levels.
During the study, intensive diabetes management was provided, with the goal of maintaining 
glycated hemoglobin levels within the age-specific ranges recommended by the American 
Diabetes Association. The treating or referring physician had the primary responsibility for 
diabetes management. The use of noninsulin medications for glycemic control was 
prohibited.
The primary outcome was the mean area under the curve (AUC) for the stimulated C-peptide 
response during the first 2 hours of a 4-hour mixed-meal tolerance test conducted at 12 
months, with the response expressed in picomoles per milliliter.21 These assessments were 
completed in August 2008, at which time analysis of 1-year outcomes was conducted. Safety 
outcomes focused on infusion reactions (occurring within 24 hours after an infusion), 
infections, and laboratory assessments, particularly assessments of white-cell counts and 
immunoglobulin levels. Patients were to continue follow-up for an additional year, with 
double blinding maintained.
After 21 patients had been enrolled, the Food and Drug Administration (FDA) reported 
progressive multifocal leukoencephalopathy (PML) in 2 people treated with rituximab for 
systemic lupus erythematosus. TrialNet immediately halted infusions in 5 patients who had 
recently undergone randomization and suspended enrollment for a period of approximately 2 
months (between December 2006 and February 2007). After consultation with experts in 
PML and with representatives of the FDA, the data and safety monitoring board allowed 
enrollment to resume but required the addition of careful neurologic examinations to the 
protocol.
LABORATORY TESTS
Blood samples were sent to TrialNet core laboratories for analysis. A 4-hour mixed-meal 
tolerance test was conducted at baseline and 1 year, and 2-hour mixed-meal tolerance 
testing, with samples obtained at intervals of 15 to 30 minutes, was performed at 3 months 
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and 6 months.21,22 Levels of antibodies to glutamic acid decarboxylase 65, islet-cell antigen 
512, and microinsulin (by microassay) were measured with the use of radio-immunobinding 
assays, and levels of islet-cell autoantibodies were measured with the use of indirect 
immunofluorescence. The presence of serum antibodies to hepatitis B surface antigen, 
hepatitis C, or the human immunodeficiency virus excluded potential participants. Human 
leukocyte antigen class II alleles (DRB1, DQA1, DQB1) were assessed using polymerase-
chainreaction amplification and sequence-specific hybridization. Levels of CD19+ cells 
were determined with the use of multiparameter flow cytometry. Complete blood counts 
were performed at each clinical center. Serum levels of rituximab and of human antichimeric 
antibodies were determined with the use of enzyme-linked immunosorbent assay (ELISA) 
techniques at Genentech.23 (For additional information concerning methods, see the 
Supplementary Appendix, available with the full text of this article at NEJM.org)
STATISTICAL ANALYSIS
The effectiveness analyses were based on the prespecified intention-to-treat cohort of 81 
patients that excluded 1 patient whose consent was withdrawn before administration of the 
initial infusion and 5 patients whose infusions were stopped as a result of the PML safety 
alert. The safety cohort consists of all 87 patients who underwent randomization. The 
prespecified primary analysis was a comparison of the C-peptide levels, calculated as 
loge([mean C peptide]+1) at baseline and at 12 months in an analysis of covariance adjusted 
for age and sex. Baseline age, sex, C-peptide level, and glycated hemoglobin level were 
prespecified subgroup factors. Secondary analyses included the overall difference between 
groups in a normal errors repeated-measures model. The geometric mean C-peptide level 
was obtained from the inverse transformation. The mean rate of change over a period of 3 to 
12 months was estimated with the use of a mixed-effects random coefficient model (for 
details, see the Supplementary Appendix).24
The originally planned enrollment target was 66 patients, which would provide 85% power 
to detect a 65% between-group difference in the geometric mean for the level of C peptide at 
the 0.05 level (one-sided test), assuming a 10% rate of loss to follow-up and a 2:1 ratio for 
assignments to the rituximab and placebo groups.21 Screening was closed after this target 
was reached, allowing for the PML interruptions, but additional patients who had already 
begun the screening process were allowed to enroll.
Results
PATIENTS
Of the 87 patients who underwent randomization, the predefined intention-to-treat cohort 
included 81 patients (Fig. 1 and Table 1). Three patients did not complete the 1-year mixed-
meal tolerance test (1 because of withdrawal of consent, 1 because of pregnancy, and 1 
because of difficulty with placement of the intravenous catheter); thus, 78 patients were 
included in the analysis of the primary outcome.
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EFFECTIVENESS
At 1 year, the mean AUC for the level of C peptide at 2 hours in the rituximab group was 
0.56 pmol per milliliter (95% confidence interval [CI], 0.50 to 0.63), as compared with 0.47 
pmol per milliliter (95% CI, 0.39 to 0.55) in the placebo group (Fig. 2A), making the mean 
level for the treatment group 20% higher than that for the placebo group (95% CI, >2 to 
infinity; P = 0.03). The results were similar at 4 hours (P = 0.009) and among the 71 patients 
who received all four infusions (P = 0.004). The patients receiving rituximab also had higher 
absolute levels of C peptide at 3, 6, and 12 months, with the greatest differences at 6 and 12 
months (nominal P = 0.03 for both comparisons) and over all the time points in aggregate 
(P<0.001).
In the rituximab group, the geometric mean C-peptide value initially improved from baseline 
(Fig. 2A). Starting with the value at 3 months, the average rate of decline in C-peptide levels 
calculated as loge([mean C peptide]+1) was similar in the two groups (P = 0.27), as shown 
in Figure 2A. However, in an analysis of the log values alone (without +1), the level of C 
peptide in the rituximab group declined at a rate of 37.7% per year (95% CI, 23.5 to 49.4), 
whereas that in the placebo group declined at a rate of 55.8% per year (95% CI, 42.1 to 66.2; 
P = 0.03).
As compared with the placebo group, the rituximab group had lower levels of glycated 
hemoglobin over the 12-month period (6.76±1.24% vs. 7.00±1.30%, P<0.001) (Fig. 2B) and 
required lower doses of insulin (0.39±0.22 U per kilogram of body weight vs. 0.48±0.23 U 
per kilogram, P<0.001) (Fig. 2C). Using the change in the t-test statistic value in the 
repeated-measures model without, and then with, adjustment for the overall and baseline C-
peptide values, we found that over the 12-month period, 34% of the between-group 
difference in the change in the glycated hemoglobin level and 34% of the between-group 
difference in the change in the insulin dose were explained by the difference in C-peptide 
levels between the two groups.
CD19+ cells were depleted by rituximab (P<0.001 for the comparison with placebo), 
indicating B-cell depletion, and gradually recovered over the course of 12 months (Fig. 2D); 
CD19+ cells were relatively stable in the placebo group. The difference between the two 
study groups in the number of CD19+ cells at 3 months explained 97% of the difference 
between groups in C-peptide levels at 12 months, the difference in the number of CD19+ 
cells at 6 months explained 88% of the difference in C-peptide levels at 12 months, and the 
difference in the number of CD19+ cells at 12 months explained only 8% of the difference 
in C-peptide levels at 12 months.
The ratio of the geometric mean AUC for the C-peptide levels at 12 months for the 
rituximab group to that of the control group was similar within subgroups (see Fig. A in the 
Supplementary Appendix). There was no significant heterogeneity among subgroups.
ADVERSE EVENTS AND SAFETY
During the first infusion, 93% of patients given rituximab had adverse reactions, as 
compared with 23% of those given placebo (Table 2). For subsequent infusions, the rate of 
reactions was similar in the two study groups, although the specific types of infusion 
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reactions differed between the groups (for more information, see the Supplementary 
Appendix).
In all, 57 patients in the rituximab group reported 392 adverse events, whereas 30 patients in 
the placebo group reported 148 adverse events. Most adverse events were grade 1 or grade 2; 
none were grade 4. For adverse events that were grade 2 or higher, the rate ratios and odds 
ratios were close to 1.0, except in the case of leukopenia, which occurred more frequently in 
the rituximab group; given the small numbers of patients, this difference was not significant. 
Adverse events of grade 3 occurred in six patients in the rituximab group and two in the 
placebo group (see the Supplementary Appendix), with risk ratios close to 1.0. Neutrophil 
counts were low in several patients at baseline, but neither the rate of neutropenia nor the 
absolute neutrophil count differed significantly between the groups at any time.
IgM levels fell in the rituximab group, an effect that persisted at 1 year (P<0.001 for the 
comparison with the placebo group) (Fig. 2E). After the recovery of B cells, an IgM 
response to immunization with a neoantigen (phiX174) was noted (see Table A in the 
Supplementary Appendix). At 3 months, the IgG levels in patients who received rituximab 
were an average of 45.8 mg per deciliter higher than those in patients who received placebo 
(a difference of 5%; P = 0.048); neither the difference after adjustment for multiple 
comparisons nor the differences at 6 months and at 12 months were significant. None of the 
patients required treatment for hypogammaglobulinemia, and no adverse effects on routine 
laboratory measures were noted. (Additional data on adverse events are available in Tables 
B, C, and D in the Supplementary Appendix.)
At 6 months, the mean serum rituximab level was higher in the subgroup of patients who 
had received all four infusions than in the overall rituximab group (4363±13417 ng per 
milliliter [34 patients] vs. 3968±12725 ng per milliliter [38 patients]); however, the levels 
were similar at 9 months (577±288 ng per milliliter [22 patients] and 567±215 ng milliliter 
[25 patients], respectively). Three patients, none of whom had human antichimeric 
antibodies at baseline, had measurable levels of these antibodies at 6 months.
DISCUSSION
The results of our study support the hypothesis that B lymphocytes play a role in the 
pathogenesis of type 1 diabetes mellitus. A single course of rituximab administered soon 
after diagnosis appears to preserve insulin secretion in part for at least 1 year. In addition to 
the improvement in C-peptide levels, the glycated hemoglobin level and the insulin dose 
were both significantly lower in the rituximab group than in the placebo group. Analyses 
suggest that the effects of treatment on the glycated hemoglobin level and insulin dose were 
related to the preservation of C-peptide levels.
The most recent and comparable trials assessing the use of antibodies to treat early type 1 
diabetes used humanized anti-CD3 antibodies.5,6 The study reported by Herold et al.6 was 
most similar to ours in that the investigators used a mixed-meal tolerance test to assess levels 
of C peptide; they noted that the mean AUC for C-peptide level fell in the placebo group 
from 133.2 nmol per liter at baseline to 66.7 nmol per liter at 12 months, a decline of 
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approximately 50% per year, whereas it rose slightly in the treatment group, from 111.5 
nmol per liter to 114.2 nmol per liter. At 12 months, the level of C peptide was 71% higher 
in patients receiving treatment than in those receiving placebo. We observed a difference of 
20% in our trial. The glycated hemoglobin level and the insulin dose required also improved,
6
 but slightly less than in our trial. In the study by Herold et al., as in ours, the average 
insulin dose at 12 months was less than 0.5 units per kilogram of body weight, indicating a 
clinical remission, as defined in the study by Herold et al. and in another study.25
It is difficult to make a true comparison between the studies of anti-CD3 antibody and our 
study of anti-CD20 antibody because of some critical differences in design. In the study by 
Her-old et al.,6 patients were younger than in our study, and they started treatment earlier 
(within 6 weeks after diagnosis vs. approximately 11 weeks in our study); in the study by 
Keymeulen et al.,5 patients began treatment even earlier (within 4 weeks after diagnosis). 
Although blinding was incomplete in our trial, there was no attempt at blinding in the study 
by Herold et al. The high incidence of anti-idiotype antibodies reported by Herold et al. 
(50% at 1 month, although the antibodies had disappeared by 12 months) might affect future 
courses of treatment. An important aspect of the study by Herold et al. was hospitalization 
for a 14-day course of infusion; there was also a higher frequency of adverse events than in 
the present study, which may mean that their approach was more arduous for patients. A 
direct comparison would be needed to assess the merits of each approach.
Subgroup analyses in our trial hint at a greater response in children and adolescents than in 
adults, although the difference was not significant (for details, see the Supplementary 
Appendix). This finding might be due to a more rapid reduction in the AUC for C peptide in 
younger patients. Until such results are confirmed, we believe that in future trials that 
examine the effect of treatment on C-peptide levels it would be prudent to stratify patients 
according to age or adjust analyses for age.
The actual mechanism of the effect of rituximab in type 1 diabetes is uncertain. We 
speculate that rituximab may reduce the production of cytokines that augment the immune 
response locally within the pancreas or the peripancreatic lymph nodes. It is also possible 
that the antigen presentation provided by B lymphocytes, which is required for continued T-
lymphocyte action, is altered by rituximab.
Human antichimeric antibodies developed in 3 of the 56 patients who received rituximab 
(5%) — a lower rate than those reported among patients with other diagnoses who have 
received rituximab (24.6% in patients with multiple sclerosis and 35% in patients with 
systemic lupus)26; however, the rate in our study is similar to the reported rates in patients 
with cancer and those with rheumatoid arthritis.27 Our three patients in whom human 
antichimeric antibodies developed had vigorous reactions to the first dose of rituximab and 
did not complete the initial dose or receive subsequent doses; consequently, all had 
subtherapeutic levels of rituximab.
Infusion reactions were the most frequent adverse events in our study, and they were limited 
to the first infusion in 38 patients. The reaction to the first dose is primarily a consequence 
of increased release of cytokines.28 One patient in our study had an adverse event reported 
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as anaphylaxis, which was consistent with the cytokine-release syndrome, and resolved 
without incident. Although corticosteroids are reported to reduce the incidence and severity 
of infusion reactions with rituximab,29 we did not use corticosteroids in our study; however, 
infusion reactions were generally mild and dissipated with a slowing of the infusion rate. 
The reactions we observed were similar to those seen in a recent trial of rituximab for the 
treatment of multiple sclerosis, in which corticosteroids were also not used.30
Increased rates of neutropenia and infection were not observed in patients in the rituximab 
group as compared with those in the placebo group. The vehicle in which rituximab was 
administered was a saline solution without additional protein. It is conceivable that the 
neutropenia reported in other trials was caused by therapeutic agents that patients received 
along with the rituximab.31 The absence of an increase in rituximab-associated infections in 
our study is consistent with the findings in other studies that avoided the use of both 
immunosuppressive agents and corticosteroids.30 However, our sample was too small to 
detect rare infections, such as PML, and other uncommon adverse events. Careful attention, 
larger studies, and longer periods of follow-up will be needed to obtain better estimates of 
the risks of adverse events.
The reduction in IgM levels, which is consistent with the findings in previous studies of 
rituximab in which IgM levels were measured,30,32 suggests that rituximab is more effective 
in reducing the B-lymphocyte population than in reducing the number of cells that secrete 
IgG. The IgM response reported in patients given the neoantigen phiX174 at the time of B-
cell recovery suggests that the immune system recovers.33,34 We have no explanation for the 
slight increase we observed in IgG levels, but we believe it is unlikely to be clinically 
meaningful; in other studies of rituximab there has been no change in IgG levels.30,32
This phase 2 study shows that a therapy that targets B cells may have a beneficial effect on 
beta-cell function in early type 1 diabetes. It is unlikely that treatment with rituximab as 
administered in this study would be optimal. We observed an initial improvement shortly 
after the administration of rituximab but with a subsequent resumption in the decline of the 
AUC for C peptide. Neither repeat nor long-term administration of rituximab was attempted, 
since information concerning the relative efficacy or safety of such an approach was lacking. 
Given our results, we believe that other anti–B-lymphocyte agents should be tested — for 
example, humanized anti-CD20 antibodies.35 Whether anti–B-lymphocyte therapy would 
prevent or delay diabetes in patients with autoantibodies, dysglycemia, or both is currently 
unknown.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Enrollment, Randomization, and Follow-up of Study Participants.
Between May 2006 and August 2007, a total of 126 patients were screened and 87 
underwent randomization. Of the 87 patients who underwent randomization, 81 composed 
the intention-to-treat cohort, of whom 78 contributed to the primary effectiveness analyses at 
12 months. In 5 of the 6 patients who were excluded, infusions were stopped after an FDA 
safety alert concerning the development of progressive multifocal leukoencephalopathy in 
other study populations receiving rituximab; in the other patient, parental consent was 
withdrawn before administration of the initial infusion.
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Figure 2. Effects of Rituximab on C-Peptide Level, Glycated Hemoglobin Level, Insulin Dose 
Required, CD19+ Cell Counts, and IgM Level.
For each panel, 95% confidence limits are shown at each time point within each group.
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Table 1.
Characteristics of the Study Groups.*
Rituximab (N = 57) Placebo (N = 30)
Age — yr
 Mean 19.0±8.6 17.3±7.8
 Median 16 14
 Range 8–40 9–38
Male sex — no. of patients (%) 36 (63) 18 (60)
Race or ethnic group — no. of patients (%)†
 White 55 (96) 29 (97)
 Non-Hispanic 54 (95) 27 (90)
No. of autoantibodies — no. of patients (%)
 1 10 (18) 3 (10)
 2 18 (32) 7 (23)
 3 17 (30) 9 (30)
 4 12 (21) 11 (37)
No. of days since diagnosis 80±22 83±19
No. of days from diagnosis to first infusion
 Median 81 91
 Range 37–137 34–109
Weight (kg) 66.0±21.9 58.0±16.8
Body-mass index 23.2±5.2 21.2±4.3
Total white cells — per mm3 5500±1500 4900±1200
CD19+ B cells lymphocytes — per mm3 275.23±134.74 338.02±226.13
CD20+ B cells lymphocytes — per mm3 268.58±127.41 295.85±122.15
Mean AUC for C peptide — pmol/ml 0.75±0.39 0.74±0.37
Glycated hemoglobin at baseline — % 7.31±1.46 7.08±1.28
Total insulin dose (units/kg) 0.37±0.24 0.38±0.22
Diabetes-associated HLA alleles present — no. of patients (%)
 DR3–DQ2 25 (44) 12 (40)
 DR4–DQ8 19 (33) 14 (47)
 DR3–DQ2 and DR4–DQ8 12 (21) 7 (23)
Received all 4 full infusions — no. of patients (%) 46 (81) 28 (93)
*
Plus–minus values are means ±SD. The body-mass index is the weight in kilograms divided by the square of the height in meters. AUC denotes 
area under the curve.
†
Race was self-reported.
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Table 2.
Number of Patients with Infusion-Related Events According to Study Group.*
Event Rituximab (N = 57) Control (N = 30) P Value†
number (percent)
Patients receiving first infusion 56 (98) 30 (100)
Patients with one or more events 52 (93) 7 (23) <0.001
Fever 12 (21) 1 (3) 0.02
Cough 3 (5) 0 0.27
Shortness of breath 4 (7)‡ 1 (3) 0.43
Hypotension 13 (23) 1 (3) 0.01
Hypertension 6 (11) 0 0.07
Tachycardia 12 (21) 0 0.004
Rash 21 (38)‡ 0 <0.001
Pruritus 18 (32) 0 <0.001
Vomiting 10 (18) 0 0.01
Nausea 18 (32) 1 (3) 0.001
Other 22 (39) 3 (10) 0.003
Patients receiving more than one infusion 51 (89) 29 (97)
Patients with one or more events during second, third, or fourth infusion 14 (27) 8 (28) 0.61
Fever 1 (2) 1 (3) 0.88
Cough 0 1 (3) 1.00
Shortness of breath 0 0 NA
Hypotension 7 (14) 5 (17) 0.78
Hypertension 0 0 NA
Tachycardia 1 (2) 0 0.64
Rash 1 (2) 0 0.64
Pruritus 1 (2) 0 0.64
Vomiting 0 0 NA
Nausea 0 0 NA
Other 4 (8) 4 (14) 0.89
*
Rituximab or placebo was administered at a rate of 50 mg per hour. If infusion-related events did not occur, the infusion rate could be increased in 
increments of 50 mg per hour every 30 minutes to a maximum of 400 mg per hour. If an infusion rate of 400 mg per hour was tolerated, subsequent 
infusions started at a rate of 100 mg per hour and were increased by 100 mg per hour every 30 minutes until a rate of 400 mg per hour was reached. 
For mild infusion reactions, the rate of infusion was slowed or temporarily interrupted and was resumed at half the previous rate on alleviation of 
symptoms. For moderate or severe infusion reactions, the infusion was not restarted and subsequent infusions were not administered. One patient 
could have multiple events. NA denotes not applicable.
†
P values are one-sided and were calculated with the use of Fisher’s exact test.
‡One patient had a grade 3 infusion reaction consisting of shortness of breath and rash.
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